iBio, Inc. (NYSE AMEX: IBIO)
, the company commercializing the iBioLaunch™ Platform for vaccines and biotherapeutics, announced that its president, Mr. Robert Erwin, will present at SEVEN; Noble Financial Capital Markets’ Seventh Annual Equity Conference, at the Hard Rock Hotel in Hollywood, Florida, on Monday, May 16, 2011 at 9:30 a.m. Eastern Time.
At the time of the presentation, a live audio and high-definition video webcast of iBio’s presentation and a copy of the presentation materials will be available on the Company's web site
, or through the Noble Financial websites:
. iBio recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will also be archived on
for 90 days following the event.
About iBio, Inc.
iBio, Inc. is a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs. Additionally, the technology is ideally suited for complex proteins and for applications where speed, scalability, and surge capacity are important. Further information is available at
About Noble Financial
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, New Jersey, St Louis, and Boca Raton. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in late spring featuring 120 – 150 presenting companies from across North America and total attendance of close to 600. For more information:
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.